Evaluation of Pemafibrate Treatment in Improving Liver Function and Lipid Profiles in Patients with Steatotic Liver Disease: Case Series Study
Background: The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) has tripled over the past 20 years. However, effective treatments for MASLD and MASH other than diet, exercise, pioglitazone, and tocopherol nicotinate are lacking. This single-arm study investigated the effects of pemafibrate treatment on lipid levels, liver function, diabetes, and weight-related changes in patients with steatotic liver disease.
Authors
- Yuma Tamura (ORCID: https://orcid.org/0000-0002-6439-3515)
- Shinji Kitahama
- Takanori Yasu (ORCID: https://orcid.org/0000-0002-1940-2347)
- Susumu Ogawa (ORCID: https://orcid.org/0000-0001-5832-8314)
- Tomoki Furuya (ORCID: https://orcid.org/0000-0003-4059-3827)
Institutions
- Tokyo Metropolitan Institute of Gerontology (JP)
- Dokkyo Medical University (JP)
Publication Details
- Journal
- Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
- Published
- 2025-01-01
- DOI
- https://doi.org/10.3999/jscpt.56.3_142
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00